FNY Investment Advisers’s Edwards Lifesciences EW Stock Holding History

FNY Investment Advisers’s Portfolio EW Stock Details EW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-1,940	Closed	-$150K	–	1086
2025 Q3	$150K	Buy	+1,940	New	+$152K	0.05%	313
2024 Q4	–	Sell	-138	Closed	-$9K	–	734
2024 Q3	$9K	Buy	+138	New	+$10K	﹤0.01%	511
2023 Q2	–	Sell	-25	Closed	-$2K	–	579
2023 Q1	$2K	Hold	25	–	–	﹤0.01%	467
2022 Q4	$1K	Buy	+25	New	+$1.93K	﹤0.01%	445

Other funds holding EW

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

FNY Investment Advisers's EW Position: Q4 2025 in Review

FNY Investment Advisers sold out of Edwards Lifesciences (EW) in Q4 2025, closing a stake of 1,940 shares — an estimated $150K sold.

FNY Investment Advisers first reported a position in EW in Q4 2022 and held it in 4 quarters. The position peaked at $150K in Q3 2025. 1,313 funds tracked by Wall St. Rank hold EW as of Q4 2025.

FNY Investment Advisers reported no remaining Edwards Lifesciences position as of Q4 2025 after selling out during the quarter.
FNY Investment Advisers sold 1,940 Edwards Lifesciences shares in Q4 2025, an estimated $150K.
FNY Investment Advisers first reported a position in Edwards Lifesciences in Q4 2022 and held it in 4 quarters.
FNY Investment Advisers's Edwards Lifesciences position peaked at $150K in Q3 2025.
1,313 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q4 2025.

Based on FNY Investment Advisers's 13F filing for Q4 2025, filed 16 Jan 2026.